These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 29446164)

  • 1. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis.
    Maki N; Nishie W; Takazawa M; Kakurai M; Yamada T; Umemoto N; Kawase M; Izumi K; Shimizu H; Demitsu T
    J Dermatol; 2018 May; 45(5):600-602. PubMed ID: 29446164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
    Nishie W
    Immunol Med; 2019 Mar; 42(1):22-28. PubMed ID: 31169082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.
    Mai Y; Nishie W; Izumi K; Yoshimoto N; Morita Y; Watanabe M; Toyonaga E; Ujiie H; Iwata H; Fujita Y; Nomura T; Sato-Matsumura KC; Shimizu S; Shimizu H
    Br J Dermatol; 2018 Sep; 179(3):790-791. PubMed ID: 29624639
    [No Abstract]   [Full Text] [Related]  

  • 5. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
    Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
    Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teneligliptin-associated bullous pemphigoid in an elderly man with diabetes.
    Guliani A; Bishnoi A; Aggarwal D; Parsad D
    Postgrad Med J; 2018 Nov; 94(1117):662-663. PubMed ID: 30317183
    [No Abstract]   [Full Text] [Related]  

  • 9. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.
    Lindgren O; Varpuluoma O; Tuusa J; Ilonen J; Huilaja L; Kokkonen N; Tasanen K
    Acta Derm Venereol; 2019 May; 99(6):602-609. PubMed ID: 30848289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
    Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
    Front Immunol; 2018; 9():542. PubMed ID: 29706950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid showing positive autoantibody responses to multiple epitopes.
    Kitao R; Fukumoto T; Hashimoto T; Izumi K; Jimbo H; Takemori C; Nishigori C
    J Dermatol Sci; 2021 Sep; 103(3):190-192. PubMed ID: 34489165
    [No Abstract]   [Full Text] [Related]  

  • 12. Βullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?
    Patsatsi A; Kyriakou A; Meltzanidou P; Trigoni A; Lamprou F; Kokolios M; Giannakou A
    Eur J Dermatol; 2018 Oct; 28(5):711-713. PubMed ID: 30325322
    [No Abstract]   [Full Text] [Related]  

  • 13. Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading.
    Takama H; Yoshida M; Izumi K; Yanagishita T; Muto J; Ohshima Y; Nishie W; Shimizu H; Akiyama M; Watanabe D
    Acta Derm Venereol; 2018 Nov; 98(10):983-984. PubMed ID: 30085319
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    Muramatsu K; Zheng M; Yoshimoto N; Ito T; Ujiie I; Iwata H; Shimizu H; Ujiie H
    J Dermatol Sci; 2020 Oct; 100(1):23-30. PubMed ID: 32843228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement.
    Kage Y; Yamaguchi Y; Uchida T; Izumi K; Nishie W; Shimizu H; Ishii N; Hashimoto T; Aihara M
    J Dermatol; 2018 Jul; 45(7):e205-e206. PubMed ID: 29380425
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
    Sawada K; Sawada T; Kobayashi T; Fujiki A; Matsushita T; Kawara S; Izumi K; Nishie W; Shimizu H; Takehara K; Hamaguchi Y
    Immunol Med; 2021 Mar; 44(1):53-55. PubMed ID: 32634333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid.
    Izumi K; Nishie W; Mai Y; Wada M; Natsuga K; Ujiie H; Iwata H; Yamagami J; Shimizu H
    J Invest Dermatol; 2016 Nov; 136(11):2201-2210. PubMed ID: 27424319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epitope-spreading phenomena in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.
    García-Díez I; España A; Iranzo P
    Br J Dermatol; 2019 May; 180(5):1267-1268. PubMed ID: 30675718
    [No Abstract]   [Full Text] [Related]  

  • 19. Dipeptidyl Peptidase 4 Inhibitor‒Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin.
    Tuusa J; Kokkonen N; Mattila A; Huilaja L; Varpuluoma O; Rannikko S; Glumoff V; Miettunen J; Tasanen K
    J Invest Dermatol; 2023 Jan; 143(1):78-86.e12. PubMed ID: 35921900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl Peptidase-4 Inhibitor Induced Bullous Pemphigoid Complicated by Acquired Reactive Perforating Dermatosis.
    Gambichler T; Espey B; Doerler M; Stranzenbach R
    Actas Dermosifiliogr; 2022 Oct; 113(9):914-915. PubMed ID: 35636509
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.